The most critical data in a high-risk pregnancy is often the hardest to get. It requires a mother to travel to a clinic, lie still for an extended period, and be hooked up to a cardiotocography machine. Connected Health Development, a Lausanne-based medtech startup, is betting that a washable smart-textile belt worn at home can deliver that data with clinical-grade reliability, shifting monitoring from a hospital event to a continuous, remote process [CHD, May 2026].
The hardware wedge
CHD’s product, called MONI2, is a belt designed to be worn comfortably under clothing. Its primary function is to collect a suite of physiological signals that are standard in obstetric care but typically confined to clinical settings. The company reports the device is engineered to capture fetal and maternal electrocardiograms (ECG), uterine contraction patterns, fetal movements, and even fetal position [CHD, May 2026]. The ambition is to package this multi-parameter data collection into a consumer-friendly form factor that is machine-washable, a practical consideration for daily use over months [Finsmes, October 2026]. For CHD, the hardware is the essential wedge into a regulated market; without a reliable sensor, the software platform has nothing to analyze.
A dual-track regulatory path
The company has outlined a phased commercialization strategy that reflects the significant regulatory hurdles in medical devices. Its first major milestone is the development of functional prototypes, targeted for the second quarter of 2027 [StartupT先icker, October 2026]. From there, CHD plans two parallel tracks: a direct-to-consumer version for general wellness, planned for early 2028, and a medical device version seeking clearance from the U.S. Food and Drug Administration by the end of 2029 [StartupT先icker, October 2026]. This dual-path approach is common in digital health, allowing for earlier market feedback and revenue while navigating the longer, more rigorous clinical validation required for a prescription device. The company’s early backing from Swiss accelerator and investor Venture Kick, totaling approximately $160,000, is earmarked for this prototype development and testing phase [Tech.eu, October 2026].
The clinical team anchoring the bet
While the founding structure is not detailed in public records, CHD’s initial leadership team appears built to bridge technical development and clinical credibility. This is critical for any device making diagnostic claims.
| Role | Name | Reported Expertise |
|---|---|---|
| CEO | Laurent Vandebrouck | Entrepreneurship and smart-textile digital health services [Tech.eu, October 2026] |
| Chief Medical Officer | Prof. Nicolas Sananès | Clinical key opinion leader in gynecology [StartupT先icker, October 2026] |
| Chief Scientific Officer | Dr. Marc Salomon | Clinical key opinion leader with cardiology expertise [StartupT先icker, October 2026] |
The presence of established clinical figures like Sananès and Salomon is a tangible asset. It not only guides product development toward clinical utility but also aids in forming the essential partnerships with hospital systems for validation studies. CHD has already announced a collaboration with the Clinical Investigation Center for Innovative Technology (CIC-IT) to focus on women’s health and high-risk pregnancies [CHD, May 2026].
The validation mountain ahead
The gap between a promising prototype and an FDA-cleared medical device is vast, and CHD’s timeline acknowledges that climb. The core technical and clinical risks are substantial.
- Signal fidelity. Capturing a clean fetal ECG through layers of clothing and amid maternal movement at home is a formidable biomedical engineering challenge. The belt must prove its data is equivalent to that of stationary hospital equipment.
- Algorithm validation. The platform’s proposed predictive indicators for risks like preterm birth will require large-scale clinical studies to demonstrate statistical significance and gain regulatory approval.
- Commercial focus. With a consumer version planned before the medical device, there is a risk of resource dilution. The company must navigate distinct development, marketing, and support pathways for two different product classes.
Success hinges on executing the planned studies and securing the significantly larger funding round,reportedly targeting €1 million,that the company indicated was in negotiation back in June 2026 [BioAlps, June 2026].
The patient population here is clear: pregnant individuals, particularly those classified as high-risk due to conditions like hypertension, diabetes, or a history of preterm birth. For them, the current standard of care involves frequent, often stressful, trips to a clinic or hospital for monitoring. This disrupts work and family life and can delay the detection of concerning trends that occur between appointments. CHD’s bet is that continuous, remote data can provide a more complete picture, offering peace of mind and enabling clinicians to intervene earlier if needed. The next twelve months, leading to those first functional prototypes, will be the first real test of whether the comfort of a washable belt can be matched by the clinical rigor it promises.
Sources
- [CHD, May 2026] CHD selected by Venture Kick and receives funding support | https://chdgroup.ch/en/2026/05/05/chd-selected-by-venture-kick-and-receives-funding-support/
- [Finsmes, October 2026] CHD Raises $150K in Funding | https://www.finsmes.com/2026/10/chd-raises-150k-in-funding.html
- [StartupT先icker, October 2026] CHF 150,000 to bring CHD pregnancy monitoring into patients’ homes | https://www.startupticker.ch/en/news/chf-150-000-to-bring-chd-pregnancy-monitoring-into-patients-homes
- [Tech.eu, October 2026] Venture Kick backs CHD with €160K to advance remote pregnancy monitoring | https://tech.eu/2026/10/26/venture-kick-backs-chd-with-eur160k-to-advance-remote-pregnancy-monitoring/
- [BioAlps, June 2026] CHD signs a CLA (Convertible Loan Agreement) with Venture Kick | https://bioalps.org/chd-signs-a-cla-convertible-loan-agreement-with-venture-kick/
- [CHD, May 2026] CHD and CIC-IT join forces in women’s health and high-risk pregnancies | https://chdgroup.ch/en/2026/05/07/chd-and-cic-it-join-forces-in-womens-health-and-high-risk-pregnancies/